检索

期
标题
作者
卷 26, 编号 1 (2024)
Safety and efficacy of ribociclib in combination with letrozole in an extended population of patients with HR+/HER2- advanced breast cancer: analysis of data from a subgroup of patients from Russia in the phase lllb CompLEEment-1 study
Zhukova L., Bolotina L., Dvornichenko V., Fadeeva N., Ganshina I., Grechukhina K., Hasanova A., Kislov N., Kudryavtsev I., Manikhas A., Musaeva N., Nizhegorodtseva A., Sadikova O., Sakaeva D., Snegovoy A., Stroyakovskiy D., Tjulandin S., Trishkina E., Vladimirova L., Volkov N., Kostalanova Y.
PDF
(Rus)
卷 25, 编号 1 (2023)
Following in the footsteps of SABCS 2022: top 12 advanced breast cancer studies that could change our clinical practice: A review
Kolyadina I.
PDF
(Rus)
卷 26, 编号 2 (2024)
Effect of internal subtype on the efficacy of CDK4/6 inhibitor therapy in advanced HR+/HER2breast cancer: A review
Grechukhina K., Filonenko D., Sukhova M., Zhukova L.
PDF
(Rus)
卷 23, 编号 1 (2021)
Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021
Board E.
PDF
(Rus)
卷 23, 编号 1 (2021)
Piqray – basic questions at the start: whom to test? whom to treat? how to treat? Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 29th, 2021
Board E.
PDF
(Rus)
卷 22, 编号 2 (2020)
Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience
Kolyadina I., Ganshina I., Kuzmicheva S., Tekeeva A., Kolokolov J., Volkonskii M., Poddubnaya I.
PDF
(Rus) PDF
(Eng)
卷 16, 编号 3 (2014)
Personalized approach to HER2-positive advanced breast cancertherapy
Stenina M.
卷 16, 编号 3 (2014)
Modern treatment possibilities of hormone receptor-positive advanced breast cancer in postmenopausal women
Jackisch C., Llombart-Cussac A.
卷 23, 编号 2 (2021)
PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021
Board E.
PDF
(Rus)
1 - 9 的 9 信息

检索提示:

  • 检索的名词区分大小写
  • 常用字词将被忽略
  • 默认情况下只有在查询结果满足所有检索词才返回（例如，隐含AND）
  • 使用OR结合多个检索词，便于查找含有这些检索词的文章，例如education OR research
  • 使用括号来创建更复杂的查询; 例如：archive ((journal OR conference) NOT theses)
  • 使用引号检索一个完整的词组; 例如： "open access publishing"
  • 使用-或者NOT排除一个检索词; 例如：online -politics or online NOT politics
  • 在检索词里使用 *作为通配符匹配任何字符序列; 例如., soci* morality 将符合含有 "sociological" or "societal"的词语

##common.cookie##